Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
(NASDAQ: PCVX) Delayed: 52.75 +0.64 (1.23%)
Previous Close $52.11    52 Week High $ 
Open $52.00    52 Week Low $ 
Day High $53.33    P/E N/A 
Day Low $51.49    EPS $ 
Volume 247,556